Eli Lilly to Buy Merida Biosciences for $2.88 Billion
Eli Lilly agreed to buy Merida Biosciences for up to $2.88 billion in cash to strengthen its immunology pipeline. The deal adds an experimental treatment for thyroid-related autoimmune conditions. The transaction is expected to close in the fourth quarter.
Xurve View
Insights:
Xurve View
ELI LILLY & CO agreed on Monday afternoon to acquire Merida Biosciences for up to $2.88 billion in cash. The deal bolsters the pharma giant's immunology portfolio with experimental treatments for thyroid-related autoimmune conditions. The transaction ranks among the company's largest bolt-on acquisitions in 2026 as executives channel windfall profits from weight-loss drugs into pipeline expansion.
